Publications

Journal Article
Research Support, N.I.H., Extramural
Epublish 4 citations
Electronic publication date
May 6, 2022

View on Pubmed.gov 35501334 | View on doi.org 10.1038/s41598-...

Role of cathepsin K in the expression of mechanical hypersensitivity following intra-plantar inflammation.

Search for publications in this journal Sci Rep - 12(1):7108

Abstract

Persistent/chronic inflammatory pain involves multiple pathophysiological mechanisms and is far more complex than acute/momentary pain. Current therapeutics for chronic inflammatory pain are often not effective because the etiology responsible for the pain is not addressed by traditional pharmacological treatments. Cathepsin K is a cysteine protease that has mostly been studied in the context of bone and joint disorders. Previous work by others has shown that inhibition of cathepsin K activity reduces osteoarthritis-associated nociception in joints. However, the role of cathepsin K in cutaneous inflammation is understudied. We assessed the effectiveness of genetic deletion or pharmacological inhibition of cathepsin K in male mice on the expression of nocifensive behaviors after formalin injection or mechanical and thermal hypersensitivity after injection of complete Freund's adjuvant (CFA) into the mouse hind paw. Our data demonstrate that cathepsin K knockout mice (Ctsk) have a reduction in nocifensive behaviors in the formalin test. In addition, Ctsk do not develop mechanical hypersensitivity after CFA injection for up to 7 days. Moreover, we found that inhibition of cathepsin K reduced mechanical hypersensitivity after CFA injection and mRNA levels, protein levels, and cathepsin K activity levels were elevated after CFA injection. Based upon our data, cathepsin K is indicated to play a role in the expression of chemically-induced cutaneous hypersensitivity, as Ctsk mice do not develop mechanical hypersensitivity and show a reduction in nocifensive behaviors. Further research is needed to determine whether attenuating cathepsin K activity may generate a clinically relevant therapeutic.

References

Biochemistry. 2002 Jul 16;41(28):8849-59

Sci Rep. 2017 Aug 18;7(1):8703

Neurosci Bull. 2019 Jun;35(3):401-418

J Neurosci. 2016 Feb 03;36(5):1669-81

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© 2022. The Author(s).